What's Driving the CRISPR Gene Editing Market 2025-2034: Genetic Disorder Prevalence Fuels The CRISPR Gene Editing Market Growth

What Are the Projections for the Size and Growth Rate of the CRISPR Gene Editing Market?
In recent times, there has been a significant surge in the size of the CRISPR gene modification market. It is projected to expand from a valuation of $2.26 billion in 2024 to around $2.88 billion in 2025, with a compound annual growth rate (CAGR) poised at 27.4%. This substantial growth seen in the historical period is driven by several factors. These include a surging demand for genome modification technologies, a rise in public funding, an escalating number of cancer cases, an increased incidence of chronic illnesses, growing awareness about CRISPR technology, and improvements in healthcare infrastructure.

The market size of CRISPR gene editing is projected to witness tremendous growth in the coming years, increasing to a significant $7.51 billion by 2029 at a compound annual growth rate (CAGR) of 27.1%. Factors such as an increased prevalence of genetic disorders, the importance placed on precision medicine, growing investment in CRISPR research and development, a rising elderly population, and the increasing significance of gene therapy procedures contribute to growth in the predicted period. Key trends that are likely to be seen throughout this forecast period include advancements in the technology used for gene editing, increased number of research studies, developments in the discovery and making of drugs, innovative delivery methods, and the utilization of CRISPR-edited crops in agriculture.

What Is Driving the Growth Trajectory of the CRISPR Gene Editing Market?
The escalating occurrence of genetic disorders is anticipated to spur the expansion of the CRISPR gene editing market in the future. The term genetic disorder refers to a medical condition resulting from genome irregularities, which can range from a single gene mutation (monogenic) to multiple gene mutations (polygenic) or chromosomal aberrations. The increasing number of genetic disorders is attributed to causes such as genetic mutations, an aging population, and marriages between close relatives. CRISPR gene editing proves highly effective in dealing with genetic disorders by offering precise and targeted alterations to the DNA. Researchers utilize CRISPR technology to pinpoint and rectify specific mutations that are the root cause of genetic disorders, regain normal functionality, and lessen disease symptoms, evident in diseases like cystic fibrosis and sickle cell anemia. For instance, as per the Cystic Fibrosis (CF) Foundation, a non-profit based in the US, there was a significant increase in the incidence of cystic fibrosis in July 2022. In 2022, nearly 40,000 children and adults in the United States, and over 105,000 people diagnosed globally were affected by cystic fibrosis. Consequently, the escalating incidence of genetic disorders is fuelling the expansion of the CRISPR gene editing market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15549&type=smp

Which Businesses Are at the Forefront of CRISPR Gene Editing Market Development?
Major companies operating in the CRISPR gene editing market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., GenScript, Integrated DNA Technologies Inc., Takara Bio Inc., OriGene Technologies Inc., Intellia Therapeutics Inc., New England Biolabs, Synthego, Arbor Biotechnologies Inc., Rockland Immunochemicals Inc., Cellectis, Editas Medicine, Caribou Biosciences Inc., System Biosciences LLC, Applied StemCell, Addgene, Mirus Bio LLC, Excision BioTherapeutics Inc., GeneCopoeia Inc., ToolGen Inc., Cellecta Inc., CRISPR Therapeutics, ERS Genomics Limited

What Are the Latest Innovations in the CRISPR Gene Editing Market?
Major corporations in the CRISPR gene editing industry are concentrating on the creation of unique products, such as gene therapy, to expand their consumer reach, boost their sales, and increase their profits. Gene therapy is a medical procedure which treats, prevents, or cures illnesses and conditions by utilizing genes. For instance, in December 2023, Casgevy, a cell-based gene therapy was approved by the US Food and Drug Administration (FDA), a US federal agency, for treating sickle cell disease. The therapy employs CRISPR/Cas9, a type of genome editing technology and hematopoietic stem cells are modified using this technology.

How Is the CRISPR Gene Editing Market Segmented?
The CRISPR gene editing market covered in this report is segmented -

1) By Type: CRISPR-Associated Nuclease (Cas Nuclease), Guide Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA) Ligase, Restriction Endonuclease, Other Types
2) By Services: Design Tools, Plasmid And Vector, CRISPR-Associated Protein 9 (Cas9) And Guide Ribonucleic Acid (g-RNA), Delivery System Products, Other Services
3) By Technology: CRISPR Or Cas9, Zinc Finger Nucleases, Other Technologies
4) By Application: Agricultural, Biomedical, Industrial, Genome Engineering, Disease Models, Functional Genomics, Other Applications
5) By End User: Academic Institutes And Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical And Biopharmaceutical Companies

Subsegments:
1) By CRISPR-Associated Nuclease (Cas Nuclease): Cas9, Cas12, Cas13, Other Cas Nucleases
2) By Guide Ribonucleic Acid (RNA): Single-guide RNA (sgRNA), Dual-guide RNA, Synthetic Guide RNA
3) By Deoxyribonucleic Acid (DNA) Ligase: T4 DNA Ligase, E. coli DNA Ligase, Other DNA Ligases
4) By Restriction Endonuclease: Type II Restriction Enzymes, Type I And III Restriction Enzymes, Other Restriction Enzymes
5) By Other Types: CRISPR Delivery Systems, CRISPR Plasmids, CRISPR-Based Diagnostic Tools

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Where Is the CRISPR Gene Editing Market Growth Most Prominent?
North America was the largest region in the CRISPR gene editing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CRISPR gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The CRISPR Gene Editing Global Market Report?

- Market Size Analysis: Analyze the CRISPR Gene Editing Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the CRISPR Gene Editing Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall CRISPR Gene Editing Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the CRISPR Gene Editing Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15549

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.